After more than 20 years of development, bioresorbable coronary stents are close to commercialization, setting up what is sure to be a hotly contested battle for a multi-billion dollar market.
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
